TEMPUS
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the worldโs largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful.
TEMPUS
Industry:
Artificial Intelligence (AI) Biotechnology Health Care Machine Learning Medical Precision Medicine
Founded:
2015-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.tempus.com
Total Employee:
501+
Status:
Active
Contact:
(800) 976-5448
Email Addresses:
[email protected]
Total Funding:
1.35 B USD
Technology used in webpage:
IPv6 Cloudflare Hosting Google Google Cloud U.S. Server Location CrUX Top 50m Apple Mobile Web App Capable Cloudflare CDN BootstrapCDN Cloudflare
Similar Organizations
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
doc.ai
doc.ai is a digital health company designed for a new generation of medical research.
Genomind
Genomind is a personalized medicine company specializing in neuropsychiatry.
Genuity Science
Contract genomics organization offering robust data sourcing, data analytics and insights, and next gen sequencing for drug discovery.
Perceiv AI
AI-driven precision medicine, forecasting disease progression
Prenosis
Transforming clinical diagnosis with predictive intelligence.
Scailyte
True precision medicine through single-cell science
Sweetch
Sweetch is the first behavioral science company to leverage AI & EI (emotional intelligence) through its digital therapeutics solutions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-03-27 | Dawson Forte Cashmere | Dawson Forte Cashmere acquired by Tempus | N/A |
| 2023-03-09 | Mpirik | Mpirik acquired by Tempus | N/A |
| 2023-02-10 | Arterys | Arterys acquired by Tempus | N/A |
| 2022-10-05 | Arterys | Arterys acquired by Tempus | N/A |
| 2022-02-08 | Highline Sciences | Highline Sciences acquired by Tempus | N/A |
| 2019-12-11 | AKESOgen | AKESOgen acquired by Tempus | N/A |
Investors List
Ares Management
Ares Management investment in Debt Financing - Tempus
Google investment in Debt Financing - Tempus
T. Rowe Price
T. Rowe Price investment in Series G - Tempus
Novo Holdings
Novo Holdings investment in Debt Financing - Tempus
Baillie Gifford
Baillie Gifford investment in Series G - Tempus
Franklin Templeton
Franklin Templeton investment in Debt Financing - Tempus
Google investment in Series G - Tempus
Baillie Gifford
Baillie Gifford investment in Debt Financing - Tempus
Franklin Templeton
Franklin Templeton investment in Series G - Tempus
Eric Lefkofsky
Eric Lefkofsky investment in Series G - Tempus
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-06-20 | Akrivia Health | Tempus investment in Series A - Akrivia Health | 4.3 M GBP |
| 2018-04-09 | 8Trip | Tempus investment in Series C - 8Trip | 600 M CNY |
| 2017-09-27 | Exicure | Tempus investment in Venture Round - Exicure | 20 M USD |
| 2015-10-21 | Exicure | Tempus investment in Venture Round - Exicure | 14.8 M USD |
Newest Events participated
Participated in GOTO Chicago 2017
on 2017-05-01 as sponsor
Official Site Inspections
http://www.tempus.com Semrush global rank: 258.39 K Semrush visits lastest month: 158.51 K
- Host name: 146.190.199.140
- IP address: 146.190.199.140
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tempus"
Our Team | Tempus
Tempus is a leader in the field of data-driven medicine, and I am excited to work with their team to further enhance patient outcomes for individuals of all backgrounds and from all communities.โ โฆSee details»
Tempus - Crunchbase Company Profile & Funding
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help โฆSee details»
Tempus AI - Wikipedia
Tempus AI, Inc. is an American health technology company [1] founded in 2015 by Eric Lefkofsky in Chicago, Illinois. [2] It was established by Lefkofsky soon after his wife was diagnosed with โฆSee details»
Our History - Tempus
Our History. Tempus was founded in August of 2015 by Eric Lefkofsky, after his wife was diagnosed with Breast Cancer. Shortly after he founded the company in an effort to bring the power of technology and artificial intelligence to cancer โฆSee details»
Investor Relations | Tempus AI
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI, in healthcare to create Intelligent Diagnostics. โฆSee details»
Tempus AI - LinkedIn
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time ...See details»
Tempus | SoftBank Group Corp. - ใฝใใใใณใฏใฐใซใผใๆ ชๅผไผ็คพ
Tempus brings the power of data and artificial intelligence to healthcare. It has a clear mission โ to help make sure patients are on the right drug at the right time, so they can live longer and โฆSee details»
Tempus Technologies - Crunchbase Company Profile & Funding
Tempus Technologies is an expert on secure payments that delivers secure and innovative payment-processing solutions for businesses of every size. Tempus Technologies' mission is โฆSee details»
Tempus - Crunchbase Company Profile & Funding
Tempus is a decentralized community of builders, creators, and connectors led by Tempus Labs to build some of the most innovative DeFi products. Tempus is building the most important โฆSee details»
Tempus | The Healthcare Technology Report.
Shane Colley is the Chief Technology Officer at Tempus. Prior to joining Tempus, Colley was Vice President of Research and Development at R1 RCM (formerly Accretive Health), where he built and led a global organization of over 200 โฆSee details»
EXCLUSIVE: Billionaire Eric Lefkofskyโs Tempus Raises $200
Dec 10, 2020 Tempus, founded by Lefkofsky in 2015, is one of a new breed of personalized cancer diagnostic companies like Foundation Medicine and Guardant Health. The companyโs โฆSee details»
Our Technology - Tempus
Our genomic profiling services encompass a broad range of sequencing options, allowing for data-driven patient decisions.. xT: 648 gene DNA sequencing panel (includes heme โฆSee details»
Tempus is Now an In-Network Provider for Humana, Expanding โฆ
Jan 24, 2024 Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the worldโs largest โฆSee details»
Tempus - Funding, Financials, Valuation & Investors - Crunchbase
Tempus has a post-money valuation in the range of $1B to $10B as of Oct 20, 2022, ... Personalis Personalis is a contract research organization and genome-scale diagnostics services โฆSee details»
Working At Tempus: Company Overview and Culture - Zippia
Mar 14, 2024 The most common ethnicity at Tempus is White (55%). 17% of Tempus employees are Hispanic or Latino. 13% of Tempus employees are Black or African American. โฆSee details»
Tempus Hub
Tempus Hub is an online portal offering clinical and molecular data access, genomic testing, and payment solutions.See details»
Tempus touts strong growth in first quarter as a public company
Aug 7, 2024 However, Tempus reported a net loss of $552.2 million driven by $493.1 million of stock compensation and related employer payroll taxes tied to the initial public offering, the โฆSee details»
Life Sciences Technology & Solutions | Tempus
Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers. Multi-omics. Discover unique molecular โฆSee details»
Genomic Profiling - Tempus
ONCOLOGY /// GENOMIC PROFILING One platform for precision oncology. At Tempus, we are changing the way precision oncology care is delivered. By leveraging clinical and molecular โฆSee details»